Enhanced Digital Features To view enhanced digital features for this article go to Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
The first GLP-1 medication received approval from the United States Food and Drug Administration in 2005
The case series in Medicine specifically highlighted this mechanism, noting that the body water loss associated with GLP-1 agonists may be more significant than commonly appreciated
Foundayo (Orforglipron) Foundayo, approved in 2026, represents a daily pill with no dosing restrictions, offering simplicity and flexibility for users